FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial...

Area of Science:

• Oncology
• Clinical Pharmacology
• Drug Development

Background:

• Traditional oncology drug development relies on maximum tolerated dose (MTD) for dosage selection.
• This MTD-based approach often leads to suboptimal dosages for novel oncology therapeutics.
• Postmarket dosage optimization is costly and inefficient, prompting regulatory calls for change.

Purpose of the Study:

• To review innovative techniques for earlier and more effective oncology drug dosage selection.
• To highlight the limitations of the traditional MTD paradigm in modern drug development.
• To outline best practices for selecting dosages for further evaluation before registrational trials.

Main Methods:

• Discussion of fit-for-purpose techniques beyond MTD.
• Exploration of innovative trial elements like biomarkers and adaptive designs (e.g., backfill, randomized dose-expansion cohorts).
• Integration of modeling approaches, such as the clinical utility index, for quantitative decision-making.

Main Results:

• Current reliance on MTD is unsustainable for optimizing modern oncology drug dosages.
• Innovative trial designs and modeling can facilitate earlier and more informed dosage selection.
• Existing advanced strategies are underutilized in favor of the traditional MTD approach.

Conclusions:

• Earlier identification of optimal oncology drug dosages is crucial for drug development efficiency.
• Adoption of innovative trial elements and modeling techniques is recommended for improved dosage selection.
• Further development and application of these advanced methods are needed to refine oncology drug dosing strategies.